3-氨基-2-氯苯甲酸 | 108679-71-6

• 物质功能分类: 生物化工 - 氨基酸及其衍生物 - 其他氨基酸衍生物
• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 3-氨基-2-氯苯甲酸
• 中文别名: 2-氯-3-氨基苯甲酸
• 英文名称: 2-chloro-3-aminobenzoic acid
• 英文别名: 3-amino-2-chlorobenzoic acid
• CAS: 108679-71-6
• 化学式: C₇H₆ClNO₂
• 分子量: 171.583
• InChiKey: IQMIVFNEHPKEAI-UHFFFAOYSA-N

物化性质

• 熔点：
  154-160 °C(lit.)
• 沸点：
  346.5±27.0 °C(Predicted)
• 密度：
  1.476±0.06 g/cm3(Predicted)
• 稳定性/保质期：

  如果按照规格使用和储存，则不会分解，未有已知危险反应。应避免与强氧化物接触。

计算性质

• 辛醇/水分配系数(LogP)：
  1.4
• 重原子数：
  11
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  63.3
• 氢给体数：
  2
• 氢受体数：
  3

安全信息

• 危险品标志：
  Xi
• 安全说明：
  S26,S36
• 危险类别码：
  R36/37/38
• WGK Germany：
  3
• 海关编码：
  2922499990
• 危险标志：
  GHS07
• 危险性描述：
  H315,H319,H335
• 危险性防范说明：
  P261,P305 + P351 + P338
• 储存条件：
  请将贮藏器保持密封状态，并存放在阴凉干燥处。同时，确保工作环境有良好的通风或排气设施。

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: 3-Amino-2-chlorobenzoic acid
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.
H315: Causes skin irritation
H319: Causes serious eye irritation
H335: May cause respiratory irritation
P261: Avoid breathing dust/fume/gas/mist/vapours/spray
P305+P351+P338: IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses if present
and easy to do – continue rinsing

---

Section 3. Composition/information on ingredients.
Ingredient name: 3-Amino-2-chlorobenzoic acid
CAS number: 108679-71-6

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
Eye contact:
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Storage: Store in closed vessels.

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
No data
Boiling point:
Melting point: No data
Flash point: No data
Density: No data
Molecular formula: C7H6ClNO2
Molecular weight: 171.6

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides, hydrogen chloride.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  3-氨基-2-氯苯甲酸 在 硫酸 、 sodium nitrite 、 氢溴酸 、 copper(I) bromide 作用下， 以 溶剂黄146 、 水 为溶剂， 反应 1.25h， 生成 3-溴-2-氯苯甲酸
  参考文献：
  名称：

  WO2006/86229

  摘要：

  公开号：
• 作为产物：
  描述：

  2-氯-3-硝基甲苯 在 potassium permanganate 、 铂 作用下， 生成 3-氨基-2-氯苯甲酸
  参考文献：
  名称：

  The Closeness of Fit of Antibenzoate Antibodies About Haptens and the Orientation of the Haptens in Combination^1-3a

  摘要：

  DOI：

  10.1021/ja01653a028

文献信息

• HETEROCYCLIC COMPOUND
  申请人：Takeda Pharmaceutical Company Limited

  公开号：US20190169166A1

  公开（公告）日：2019-06-06

  Provided is a heterocyclic compound that may have a GCN2 inhibitory action, and is expected to be useful for the prophylaxis or treatment of GCN2 associated diseases including cancer and the like. A compound represented by the formula (I): wherein each symbol is as described in the DESCRIPTION, or a salt thereof.

  提供的是一种可能具有GCN2抑制作用的杂环化合物，预计可用于预防或治疗与GCN2相关的疾病，包括癌症等。一种由以下式（I）表示的化合物： 其中每个符号如描述中所述，或其盐。
• Pyrimidine derivatives useful as inhibitors of PKC-theta
  申请人：Barbosa J.M. Antonio

  公开号：US20060025433A1

  公开（公告）日：2006-02-02

  Disclosed are novel compounds of formula (I): wherein X, Y, R 1 , R 2 and R 3 are as defined herein, which are useful as inhibitors of PKC-theta and are thus useful for treating a variety of diseases and disorders that are mediated or sustained through the activity of PKC-theta, including immunological disorders and type II diabetes. This invention also relates to pharmaceutical compositions comprising these compounds, methods of using these compounds in the treatment of various diseases and disorders, processes for preparing these compounds and intermediates useful in these processes.

  披露了公式(I)的新颖化合物：其中X、Y、R1、R2和R3如本文所述定义，它们作为PKC-theta的抑制剂是有用的，因此可用于治疗通过PKC-theta活性介导或维持的多种疾病和失调，包括免疫失调和II型糖尿病。本发明还涉及包含这些化合物的药物组合物、使用这些化合物治疗各种疾病和失调的方法、制备这些化合物的方法以及在这些过程中有用的中间体。
• Anilides of (<i>R</i>)-Trifluoro-2-hydroxy-2-methylpropionic Acid as Inhibitors of Pyruvate Dehydrogenase Kinase
  作者：Gregory R. Bebernitz、Thomas D. Aicher、James L. Stanton、Jiaping Gao、Suraj S. Shetty、Douglas C. Knorr、Robert J. Strohschein、Jennifer Tan、Leonard J. Brand、Charles Liu、Wei H. Wang、Christine C. Vinluan、Emma L. Kaplan、Carol J. Dragland、Dominick DelGrande、Amin Islam、Robert J. Lozito、Xilin Liu、Wieslawa M. Maniara、William R. Mann

  DOI：10.1021/jm0000923

  日期：2000.6.1

  The optimization of a series of anilide derivatives of (R)-3,3, 3-trifluoro-2-hydroxy-2-methylpropionic acid as inhibitors of pyruvate dehydrogenase kinase (PDHK) is described that started from N-phenyl-3,3,3-trifluoro-2-hydroxy-2-methylpropanamide 1 (IC(50) = 35 +/- 1.4 microM). It was found that small electron-withdrawing groups on the ortho position of the anilide, i.e., chloro, acetyl, or bromo

  描述了从N-苯基-3,3开始优化一系列作为丙酮酸脱氢酶激酶（PDHK）抑制剂的（R）-3,3，3-三氟-2-羟基-2-甲基丙酸的苯胺衍生物，3-三氟-2-羟基-2-甲基丙酰胺1（IC（50）= 35 +/- 1.4 microM）。已经发现，在苯胺的邻位上的小的吸电子基团，即氯，乙酰基或溴，增加了20-40倍的效力。当苯胺在4位被吸电子基团（即羧基，羧酰胺和亚磺酰胺）取代时，该系列化合物的口服生物利用度最佳（通过AUC测定）。N-（2-氯-4-异丁基氨磺酰基苯基）-（R）-3,3,3-三氟-2-羟基-2-甲基丙酰胺（10a）在主酶分析中抑制PDHK，IC（50）为13 + /-1.5 nM，增强人成纤维细胞中[[14] C]乳酸盐氧化成（14）CO（2）的活性，口服剂量低至30 micromol / kg后2.5和5 h显着降低血液乳酸水平，并增加肌肉，肾脏，肝脏和心脏组织中的PDH。但是
• Process for the preparation of benzotriazoles
  申请人：——

  公开号：US20040019220A1

  公开（公告）日：2004-01-29

  A process for the preparation of compounds of formula (I): wherein the general symbols are as defined in claim 1, which comprises reacting a compound of formula (V): wherein R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , R 9 and R 18 are as defined in claim 1, and R 18 is especially nitro, chlorine or bromine, with an azide compound of formula (IX): wherein M and n are as defined in claim 1, especially with sodium azide.

  一种制备化合物的方法，其化学式为（I）：其中一般符号如权利要求书中所定义，包括将化合物的化学式为（V）：其中R1，R2，R3，R4，R5，R6，R7，R8，R9和R18如权利要求书中所定义，且R18特别是硝基、氯或溴，与化学式为（IX）的叠氮化合物发生反应：其中M和n如权利要求书中所定义，特别是与叠氮化钠反应。
• [EN] SUBSTITUTED QUINOLINES AND METHODS FOR TREATING CANCER<br/>[FR] QUINOLÉINES SUBSTITUÉES ET PROCÉDÉS POUR TRAITER LE CANCER
  申请人：ACTAVALON INC

  公开号：WO2018085348A1

  公开（公告）日：2018-05-11

  Substituted quinoline compounds, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of using such compounds to treat, prevent or ameliorate cancer are provided.

  提供了替代喹啉化合物、制备这种化合物的方法、包含这种化合物的药物组合物和药物，以及利用这种化合物治疗、预防或改善癌症的方法。

表征谱图